137 related articles for article (PubMed ID: 22865870)
1. Fluoroquinolones and the risk of serious arrhythmia: a population-based study.
Lapi F; Wilchesky M; Kezouh A; Benisty JI; Ernst P; Suissa S
Clin Infect Dis; 2012 Dec; 55(11):1457-65. PubMed ID: 22865870
[TBL] [Abstract][Full Text] [Related]
2. Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study.
Inghammar M; Svanström H; Melbye M; Pasternak B; Hviid A
BMJ; 2016 Feb; 352():i843. PubMed ID: 26920666
[TBL] [Abstract][Full Text] [Related]
3. Fluoroquinolone use and serious arrhythmias: A nationwide case-crossover study.
Porta L; Lee MG; Hsu WT; Hsu TC; Tsai TY; Lee CC
Resuscitation; 2019 Jun; 139():262-268. PubMed ID: 31029713
[TBL] [Abstract][Full Text] [Related]
4. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.
Chou HW; Wang JL; Chang CH; Lai CL; Lai MS; Chan KA
Clin Infect Dis; 2015 Feb; 60(4):566-77. PubMed ID: 25409476
[TBL] [Abstract][Full Text] [Related]
5. Fluoroquinolones increase the risk of serious arrhythmias: A systematic review and meta-analysis.
Liu X; Ma J; Huang L; Zhu W; Yuan P; Wan R; Hong K
Medicine (Baltimore); 2017 Nov; 96(44):e8273. PubMed ID: 29095256
[TBL] [Abstract][Full Text] [Related]
6. Association of oral ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin with the risk of serious ventricular arrhythmia: a nationwide cohort study in Korea.
Cho Y; Park HS
BMJ Open; 2018 Sep; 8(9):e020974. PubMed ID: 30269062
[TBL] [Abstract][Full Text] [Related]
7. Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case-control, case-crossover and case-time-control designs.
Zambon A; Polo Friz H; Contiero P; Corrao G
Drug Saf; 2009; 32(2):159-67. PubMed ID: 19236122
[TBL] [Abstract][Full Text] [Related]
8. Exploring the effect of transient exposure on the risk of acute events by means of time-window designs: an application to fluoroquinolone antibacterials and arrhythmia.
Corrao G; Botteri E; Bertù L; Zambon A; Favilli S
Pharmacoepidemiol Drug Saf; 2006 Jan; 15(1):31-7. PubMed ID: 15954079
[TBL] [Abstract][Full Text] [Related]
9. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort.
Wilchesky M; Ernst P; Brophy JM; Platt RW; Suissa S
Chest; 2012 Aug; 142(2):305-311. PubMed ID: 22871756
[TBL] [Abstract][Full Text] [Related]
10. Risk of acute kidney injury associated with the use of fluoroquinolones.
Bird ST; Etminan M; Brophy JM; Hartzema AG; Delaney JA
CMAJ; 2013 Jul; 185(10):E475-82. PubMed ID: 23734036
[TBL] [Abstract][Full Text] [Related]
11. Estimated Cardiac Risk Associated With Macrolides and Fluoroquinolones Decreases Substantially When Adjusting for Patient Characteristics and Comorbidities.
Polgreen LA; Riedle BN; Cavanaugh JE; Girotra S; London B; Schroeder MC; Polgreen PM
J Am Heart Assoc; 2018 Apr; 7(9):. PubMed ID: 29680825
[TBL] [Abstract][Full Text] [Related]
12. Macrolide and fluoroquinolone mediated cardiac arrhythmias: clinical considerations and comprehensive review.
Cornett E; Novitch MB; Kaye AD; Pann CA; Bangalore HS; Allred G; Bral M; Jhita PK; Kaye AM
Postgrad Med; 2017 Sep; 129(7):715-724. PubMed ID: 28770640
[TBL] [Abstract][Full Text] [Related]
13. Urinary antispasmodic use and the risks of ventricular arrhythmia and sudden death in older patients.
Wang PS; Levin R; Zhao SZ; Avorn J
J Am Geriatr Soc; 2002 Jan; 50(1):117-24. PubMed ID: 12028256
[TBL] [Abstract][Full Text] [Related]
14. Risk of gastrointestinal perforation in patients taking oral fluoroquinolone therapy: An analysis of nationally representative cohort.
Hsu SC; Chang SS; Lee MG; Lee SH; Tsai YW; Lin SC; Chen ST; Weng YC; Porta L; Wu JY; Lee CC
PLoS One; 2017; 12(9):e0183813. PubMed ID: 28873440
[TBL] [Abstract][Full Text] [Related]
15. Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study.
Kaye JA; Castellsague J; Bui CL; Calingaert B; McQuay LJ; Riera-Guardia N; Saltus CW; Quinlan S; Holick CN; Wahl PM; Suzart K; Rothman KJ; Wallander MA; Perez-Gutthann S
Pharmacotherapy; 2014; 34(4):336-49. PubMed ID: 24865821
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Respiratory Fluoroquinolones and the Risk of Sudden Cardiac Death Among Patients Receiving Hemodialysis.
Assimon MM; Pun PH; Wang LC; Al-Khatib SM; Brookhart MA; Weber DJ; Winkelmayer WC; Flythe JE
JAMA Cardiol; 2022 Jan; 7(1):75-83. PubMed ID: 34668928
[TBL] [Abstract][Full Text] [Related]
17. Severe dysglycemia with the fluoroquinolones: a class effect?
Aspinall SL; Good CB; Jiang R; McCarren M; Dong D; Cunningham FE
Clin Infect Dis; 2009 Aug; 49(3):402-8. PubMed ID: 19545207
[TBL] [Abstract][Full Text] [Related]
18. Weighing the adverse cardiac effects of fluoroquinolones: A risk perspective.
Mehrzad R; Barza M
J Clin Pharmacol; 2015 Nov; 55(11):1198-206. PubMed ID: 26011799
[TBL] [Abstract][Full Text] [Related]
19. Oral fluoroquinolones and risk of glaucoma.
Yang L; Etminan M; Mikelberg FS
J Glaucoma; 2014 Sep; 23(7):464-6. PubMed ID: 23632400
[TBL] [Abstract][Full Text] [Related]
20. BET 1: What is the incidence of cardiac arrhythmia in adult patients with acute infection prescribed fluoroquinolones?
Chan K; Fitzpatrick J
Emerg Med J; 2019 Oct; 36(10):635-638. PubMed ID: 31551305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
